Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amarin establishes new R&D facility in Mystic, Connecticut
The new office will be responsible for Amarin’s R&D activities in cardiovascular disease which includes AMR101 for hypertriglyceridemia, planned to enter Phase III in 2009. Amarin has also
The new office will be responsible for Amarin’s R&D activities in cardiovascular disease which includes AMR101 for hypertriglyceridemia, planned to enter Phase III in 2009. Amarin has also
Previously, Ms Larson served as a senior manager and director at Grant Thornton in their mergers and acquisitions advisory group. Prior to that time, Ms Larson was CFO
The positive opinion precedes the licensure of the ‘mock-up’ vaccine, which allows Celvapan to be used if the World Health Organization officially declares a pandemic. The positive opinion
In this study, the efficacy of multiple doses of 600mg of MEM 1414 on the allergen-induced asthmatic response in steroid free subjects with mild allergic asthma will be
As a result of this action, the company estimates that it will generate annual savings of approximately $5.4 million beginning in 2009. During the fourth quarter of 2008,
The randomized, double-blind, placebo-controlled, single-center, single ascending dose study will evaluate the safety and pharmacokinetic profile of SPL-017. A total of 74 healthy adult male subjects will be
The randomized, multi-center, placebo-controlled, dose-ranging study is designed to evaluate the safety, tolerability and efficacy of RX-10045 in improving the signs and symptoms of dry eye. Approximately 200
Under the terms of the development and licensing agreement ConvaTec receives exclusive global marketing and distribution rights for the Engenex negative pressure wound therapy (NPWT) system. In addition,
The Phase I single-center, multiple ascending dose study tested the safety, tolerance and pharmacodynamics of AR9281 in 24 healthy male and female volunteers. Participants were enrolled in three
The formal adoption of the positive opinion follows the Committee for Medicinal Products for Human Use recommendation previously announced in November 2008. The marketing authorization is likely to